Correction to Press Release Announcing Reverse Stock Split of Rallybio Common Stock in Connection with the Proposed Merger with Avenzo
Rallybio Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with Avenzo
Rallybio Stockholders Approve Avenzo Merger, Name Change and Reverse Split
Rallybio Q3 EPS $(0.48) Misses $(0.21) Estimate
Rallybio Declares $82.7M Special Cash Distribution To Stockholders And Pre-Funded Warrant Holders, Estimated At $13.56/Share, In Connection With Avenzo Therapeutics Merger
Rallybio Announces CFO Jonathan Lieber To Transition To Part-Time Employment Effective September 15, Remaining CFO And Principal Financial Officer; Employment To Terminate Upon Closing Of Avenzo Therapeutics Business Combination
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?
RallyBio tries again for reverse merger, this time with Avenzo
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
Rallybio To Acquire Avenzo Therapeutics; Avenzo Entered Into $215M Private Placement Financing
RALLYBIO CORP (NASDAQ:RLYB) Passes Minervini Trend and High Growth Momentum Filters
Rallybio to acquire Candid Therapeutics
Rallybio shares are trading higher after the company agreed to a merger deal with Candid Therapeutics.
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism
Candid, in a reverse merger with RallyBio, to go public
Rallybio Corporation Shares Resume Trade
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.